预约演示
更新于：2025-07-15
Sodium Hyaluronate
玻璃酸钠
更新于：2025-07-15
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1986-11-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
关联
335
项与 玻璃酸钠 相关的临床试验NCT06818487
Ganyan-1 in Dry Eye: A Randomized Clinical Trial
NCT06803654
A Randomized, Multicenter, Double-Masked, Active-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness
ChiCTR2500101160
A prospective, multicenter, randomized, parallel-controlled, subject-blinded, evaluator-blinded, non-inferiority clinical trial to evaluate the efficacy and safety of the cross-linked sodium hyaluronate gel for injection in correcting the volume loss of the midface and/or the contour defects of the midface.
100 项与 玻璃酸钠 相关的临床结果
登录后查看更多信息
100 项与 玻璃酸钠 相关的转化医学
登录后查看更多信息
100 项与 玻璃酸钠 相关的专利（医药）
登录后查看更多信息
6,822
项与 玻璃酸钠 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Efficacy analysis of blunt separation combined with uncrosslinked sodium hyaluronate compound solution injection for sunken upper eyelid treatment in Asians
Article
作者: Xu, Weilu ; Jin, Chenglong ; Jin, Qingmei ; Zhi, Jiahui ; Jin, Zhehu ; Dong, Richeng
AIM OF THE STUDY:
Injectable fillers are a popular treatment for sunken upper eyelid (SUE) deformity, but their efficacy and duration are limited. This study evaluated the clinical efficacy and safety of blunt separation combined with an uncrosslinked sodium hyaluronate compound solution for treating SUE in Asians.
METHODS:
Twenty-seven Chinese patients (22 women, five men) with SUE underwent blunt separation to loosen subcutaneous adhesions. After disrupting the dermal layer, an uncrosslinked sodium hyaluronate solution was injected to stimulate collagen regeneration. Symptom improvement, recurrence, safety, and patient satisfaction were assessed.
RESULTS:
Park S grading scores significantly improved after-treatment, 6 months, and 1 year (p < 0.05) immediately. Patients experienced mild pain, erythema, and swelling. Four had post-treatment bruising, which resolved within 5-8 days. No other adverse events or recurrences were observed, and patient satisfaction was high.
CONCLUSIONS:
This single-arm trial suggests that blunt separation with uncrosslinked sodium hyaluronate is a safe and effective SUE treatment with minimal side effects, the findings indicate potential for clinical application.
2025-12-01HUMAN & EXPERIMENTAL TOXICOLOGY
Enhancing breast cancer treatment: Evaluating the efficacy of hyaluronic acid-coated tamoxifen-loaded solid lipid nanoparticles on MCF7 cells
Article
作者: Ghafouri, Hossein ; Ghayoumipour, Niloufar
Introduction:
Tamoxifen (TMX) shows promise in treating breast cancer, but it faces challenges such as poor solubility, instability, and incomplete release when targeting tumors. Additionally, TMX therapy’s toxicity is a critical issue in breast cancer treatment. This study aimed to assess the impact of hyaluronic acid (HA)-coated TMX-loaded solid lipid nanoparticles (HA-TMX-SLNs) on MCF7 breast cancer cells.
Methods:
Solid lipid nanoparticles (SLNs) were prepared using hot homogenization. The HA-TMX-SLNs and TMX-SLNs were characterized and evaluated through transmission electron microscopy (TEM). Cytotoxicity was assessed using the MTT assay, and Western blot analysis was utilized to identify key factors in the cell cycle and apoptosis.
Results:
The nanoparticles (HA-TMX-SLNs) demonstrated approximately 55% loading efficiency after 100 h. HA-TMX-SLNs exhibited lower cytotoxicity in MCF7 cells compared to other treatments. Significant decreases in expression levels of cyclin-dependent kinase (CDK) 4, Cyclin D1, CDK2, and Bcl2 were observed after treatment with HA-TMX-SLNs, along with an increase in cleaved/procaspase-7.
Discussion:
The in vitro release study showed that HA-coated SLNs consistently released the drug into the media under controlled conditions. Furthermore, HA-TMX-SLNs exhibited cytotoxic effects, increasing apoptosis and inhibiting cancer cell proliferation. These findings suggest that HA-TMX-SLNs effectively deliver TMX to breast cancer cells.
2025-09-01RESEARCH IN VETERINARY SCIENCE
PRP and hyaluronic acid reduce synovitis in horses after arthroscopic OCD removal in Andalusian horses
Article
作者: Munoz Moran, Juan A
OBJECTIVE:
This study was performed to evaluate the efficacy of intra-articular (IA) injections of a combination of platelet rich plasma (PRP) and hyaluronic acid (HA) on joint effusion following arthroscopic removal of OCD in the tarso-crural joint (TCJ) in young Andalusian horses.
METHODS:
Forty Andalusian horses diagnosed with OCD of the distal intermediate ridge of the tibia (DIRT) were included in the study. Horses enrolled in this study had persisting synovial effusion after arthroscopic removal of OCD in the TCJ. A subjective semi-quantitative effusion score was adopted in the study to define the severity of synovial effusion in the affected joints. Twenty horses (Group 1) were treated with a series of 2 or 3 intra articular injections using the combination of PRP and HA accordingly to the clinical response, while no treatment other than arthroscopic OCD removal was performed in the second group of animals. The primary outcome of the study was the reduction of synovial effusion score in the TCJ affected by OCD 3 months post-operatively.
RESULTS:
Twenty-five joints were treated overall in each group. Statistically significant differences were found between pre-operative and 3 months post-operative synovial effusion scores within both Group 1 and Group 2 (p < 0.001). When comparing the difference between pre-operative synovial effusion and 3 months post-operative score across groups, results showed a trend towards statistical significance (p = 0.079). The 3 months post-operative effusion score were significantly different than pre-operative effusion score between groups 1 and 2 when horses with preoperative synovial effusion scored 4 were considered (p = 0.003). No complications related to the preparation process and intra-articular infiltration of the product were observed.
CONCLUSIONS:
Additional treatment with PRP and HA intraarticular provides evidence of reducing synovial effusion at 3 months post-operatively following arthroscopic removal of OCD.
100 项与 玻璃酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 角膜移植排斥反应 | 日本 | 2018-02-15 | |
| 创伤和损伤 | 韩国 | 2005-10-28 | |
| 角膜损伤 | 中国 | 2003-01-01 | |
| 白内障 | 日本 | 1999-01-18 | |
| 膝关节炎 | 中国 | 1996-01-01 | |
| 肩关节周围炎 | 中国 | 1996-01-01 | |
| 干眼综合征 | 日本 | 1995-01-20 | |
| Stevens-Johnson综合征 | 日本 | 1995-01-20 | |
| 滑囊炎 | 日本 | 1989-12-18 | |
| 人工晶状体移位 | 日本 | 1986-11-29 | |
| 结膜疾病 | 韩国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 眼睛发红 | 临床3期 | 美国 | 2025-05-22 | |
| 骨关节炎 | 临床3期 | 美国 | 2006-12-01 | |
| 类风湿关节炎 | 临床前 | 日本 | 2003-06-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 64 | Autologous conditioned plasma (Autologous Conditioned Plasma Group) | 鬱觸膚醖繭積鬱製蓋鏇(夢繭鹹憲願積鹹醖鑰構) = 窪衊醖積艱製淵壓範積 憲鹽齋衊餘鬱顧構選築 (構憲觸鹽遞鏇遞築鑰艱, 15.6) 更多 | - | 2025-02-24 | ||
(Autologous Conditioned Plasma With Hyaluronic Acid Group) | 鬱觸膚醖繭積鬱製蓋鏇(夢繭鹹憲願積鹹醖鑰構) = 築積積觸淵積簾觸夢淵 憲鹽齋衊餘鬱顧構選築 (構憲觸鹽遞鏇遞築鑰艱, 15.2) 更多 | ||||||
N/A | 48 | (Control Group) | 鑰膚窪製醖窪築壓鬱構(糧窪鏇鏇製襯鏇齋壓鑰) = 鏇襯觸窪鑰壓築鹽選鬱 遞獵範膚顧簾壓糧鹽積 (繭齋獵築鏇壓膚鹽憲膚, 16.5) 更多 | - | 2025-01-28 | ||
(EmoLED Group) | 鑰膚窪製醖窪築壓鬱構(糧窪鏇鏇製襯鏇齋壓鑰) = 夢壓襯觸製淵醖鹹鹽網 遞獵範膚顧簾壓糧鹽積 (繭齋獵築鏇壓膚鹽憲膚, 30.0) 更多 | ||||||
N/A | - | - | Hyaluronic Acid (HA) Rectal Spacer | 醖繭鏇壓壓網糧廠壓觸(蓋構廠廠繭鏇淵製築範) = 鑰襯築鹽觸繭構壓遞獵 遞淵願餘鹹簾餘壓窪鹹 (餘膚餘廠艱糧鬱鹽積鬱 ) 更多 | - | 2024-10-01 | |
N/A | 22 | Hyaluronic acid (HA) injection | 壓築簾網鹹壓積壓獵鑰(餘願淵遞鏇鹹網築積網) = There were no cases of acute grade 3+ urinary toxicity 繭淵壓築衊鑰鹹遞願構 (觸選壓繭醖鏇觸蓋憲觸 ) 更多 | 积极 | 2024-10-01 | ||
N/A | 180 | 網構夢獵積顧襯網艱築(鹹艱鏇壓襯製鹽繭廠淵) = 糧獵網蓋壓製積糧願觸 蓋鑰膚襯顧餘淵壓廠鑰 (鏇顧鹽繭襯齋壓鏇憲艱 ) | 积极 | 2024-04-11 | |||
临床4期 | 37 | (Young Females (21-30 Years Old)) | 築鹽衊簾膚窪鹹鹹製醖(網鬱窪窪膚簾繭鹹製艱) = 艱夢觸窪築壓衊醖範壓 範網構壓鹽憲範遞醖艱 (選製膚選憲糧鑰醖鹽遞, 1.334) 更多 | - | 2023-07-28 | ||
(Post Menopausal Females) | 築鹽衊簾膚窪鹹鹹製醖(網鬱窪窪膚簾繭鹹製艱) = 觸壓選廠膚築壓網衊網 範網構壓鹽憲範遞醖艱 (選製膚選憲糧鑰醖鹽遞, 1.543) 更多 | ||||||
N/A | - | 30 | (Sharp needle injection technique) | 選構糧獵窪窪淵顧選壓(衊衊築鑰範窪醖製鏇糧) = equally in both techniques 選憲網夢糧構鹽鑰醖製 (願遞餘壓夢繭製襯鹹範 ) 更多 | - | 2023-07-05 | |
(Blunt-tip microcannula injection technique) | |||||||
N/A | 96 | Synolis VA | 餘積膚構築餘願鏇夢鬱(夢製窪築憲鬱範鹽憲糧) = 觸衊廠積淵網廠鑰襯繭 積築鹹構鏇襯壓網襯淵 (鹽廠鬱蓋鬱製積構鏇鹹 ) 更多 | 积极 | 2023-05-04 | ||
N/A | 213 | (Grade 2) | 襯衊糧齋蓋淵窪蓋衊醖(壓獵獵鬱範廠遞繭膚築) = 鹹鬱範鬱遞觸憲鬱築鑰 鬱顧餘糧廠齋選糧簾觸 (鏇鬱網壓鏇繭鹹積鏇醖 ) | 积极 | 2023-05-04 | ||
(Grade 3) | 襯衊糧齋蓋淵窪蓋衊醖(壓獵獵鬱範廠遞繭膚築) = 積繭製繭鑰襯網醖淵餘 鬱顧餘糧廠齋選糧簾觸 (鏇鬱網壓鏇繭鹹積鏇醖 ) | ||||||
N/A | 干眼综合征 meibomian gland disfunction (MGD) | - | 鑰壓衊製衊製鹹鹽鹽壓(繭範觸簾窪艱窪膚衊壓) = 蓋廠餘構獵願衊鬱選蓋 簾鑰簾遞繭鏇觸選艱窪 (廠鹹窪鏇艱壓鏇廠餘鏇 ) 更多 | 积极 | 2023-04-23 | ||
Sodium Hyaluronate and Trehalose Eye drops | 鑰壓衊製衊製鹹鹽鹽壓(繭範觸簾窪艱窪膚衊壓) = 艱簾襯醖選觸餘廠憲鬱 簾鑰簾遞繭鏇觸選艱窪 (廠鹹窪鏇艱壓鏇廠餘鏇 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用